At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
Tralokinumabdrug
Likely dose
Tralokinumab 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function
In Brief
A Phase 2 clinical trial evaluating Tralokinumab for Atopic Dermatitis. Completed, enrolled 16 participants across 1 site.
Detailed Summary
Effects of tralokinumab treatment of atopic dermatitis on skin barrier function.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartSep 2020
Primary CompletionJul 2022
Study CompletionMar 2023
TodayJul 2026
First PostedSep 21, 2020
Enrollment StartSep 28, 2020
Primary CompletionJul 1, 2022
Study CompletionMar 31, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.8 years ago
Interventions
Tralokinumabdrug
2 x 300 mg Tralokinumab s.c. loading dose followed by 8 x 300 mg every 2 weeks (Q2W)